Poorly controlled hypertension is a major risk for cardiovascular morbidity and mortality, strokes, heart failure and renal failure. Despite these devastating complications, blood pressure control of p140/90 mmHg, which is above the current standard, is very poor worldwide, accounting for 34% of hypertensive patients in the United States, and 6% in other countries. The reasons for this poor control of blood pressure include lack of aggressive treatment by physicians, especially for the systolic blood pressure, drug selection and patient compliance. The blood pressure follows a circadian rhythm and is the highest between 0600 to 1200 h, when most complications occur. Long-acting drugs that extend their action to cover this vulnerable period are preferable, especially those that block the renin-angiotensin-aldosterone system, such as ACE inhibitors and angiotensin receptor blockers, and are the most effective in controlling blood pressure and preventing or reducing its cardiovascular and renal complications. With respect to the angiotensin receptor blockers, telmisartan has been demonstrated by several studies to be the longest acting among its class of drugs and to effectively prevent the early morning rise of blood pressure.
Introduction
Chronic poorly controlled hypertension is a major risk factor for cardiovascular morbidity and mortality, strokes, heart failure and renal failure. [1] [2] [3] [4] [5] Despite these known devastating complications of hypertension, blood pressure control is very poor worldwide, accounting for 34% in the United States 6 to 6% in other countries. 7 The reasons for this poor control vary greatly among different countries, but it is possible that drug selection with respect to their mechanism of action and their duration of its effect can play a significant role in the control of hypertension and the prevention of its complications. Drugs with short-to-moderate duration of action, administered in the morning, do not provide an effective 24-h blood pressure control, and especially in the following day's early morning hours when the blood pressure is the highest. 8 In addition, the mechanism of action, could have a bearing on the prevention of target organ damage from hypertension, since drugs that block the renin-angiotensinaldosterone system (RAAS) seem to provide the most benefit with respect to cardiovascular remodelling and its complications. 9 This review will focus on these two aspects: (1) Circadian variation of blood pressure, and (2) inhibition of the RAAS.
Circadian variations of blood pressure and cardiovascular events
Most biologic functions of our body follow a biologic rhythm that is characterized by its period, amplitude and phase. 10 The period is the time required to complete a full cycle, which varies from hours, to days, to months. The amplitude characterizes the highs and lows of the biologic rhythm, and the phase is the specific clocking of these biologic events. The biologic rhythm with an approximate period of 24 h is called circadian. Rhythms with shorter periods are called ultradian and those with longer periods are called infradian. The most important of them is the circadian rhythm since most of our biologic functions follow this rhythm ( Figure 1 ). This biologic clock depicts the peak times of our biologic functions and their relationship to various clinical events. With respect to cardiovascular events, the most critical period is between 0600 and 1200 h. During this period, cortisol, catecholamines, plasma renin activity, plasma angiotensin, plasma aldosterone, platelet adhesiveness, blood viscosity and blood pressure reach their peak levels. Also, arterial compliance decreases, vascular resistance increases and blood pressure reaches its highest levels. 11 The sudden blood pressure rise is the cause of most events because of the sudden vibrations of the arterial wall. Vulnerable atherosclerotic plaques can rupture releasing viscous material in the arterial lumen, which, together with the high platelet adhesiveness, can cause complete vascular occlusion, leading to acute myocardial infarction (MI) or thrombotic stroke. Plaque rupture has been demonstrated recently to follow the circadian rhythm with the highest incidence between 0600 and 1200 h. 12 In addition, vascular rupture can occur, leading to haemorrhagic stroke. A large number of studies have demonstrated that the incidence of MI, sudden death and stroke is the highest during the vulnerable period of 0600 to 1200 h. These data are summarized by Elliott 8 and depicted in Figures 2-4 . Drugs that have a long duration of action and in addition block the RAAS provide the best protection against the various cardiovascular and cerebrovascular events. 9, 11, [13] [14] [15] The reason for this is that angiotensin II (AII), besides being a potent arteriolar vasoconstrictor, and having direct proliferative effects on smooth muscle cells, also stimulates other trophic substances such as aldosterone, endothelin 1 and 3 and transforming growth factor b 1 (TGFb 1 ). In addition to its trophic effects, AII suppresses the release of antigrowth factors such as bradykinin, prostaglandin E 2 (PGE 2 ) and nitric oxide (NO).
Angiotensin receptor blockers vs angiotensin-converting enzyme inhibitors as preferred drugs
There is plenty of experimental evidence that the RAAS plays an important role in cardiovascular remodelling and end-organ damage in hypertensive patients, 9, [15] [16] [17] [18] [19] [20] leading to left ventricular hypertrophy (LVH), congestive heart failure (CHF), . It is logical, therefore, to expect that blocking the RAAS will lower the blood pressure, improve the symptoms of heart failure, prevent the further deterioration of renal function and reduce the cardiovascular morbidity and mortality. Indeed, several large prospective studies have shown this to be the case. [21] [22] [23] [24] [25] The RAAS can be blocked at different stages of its cascade by renin inhibitors, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) ( Figure 5 ). Although both the ACEIs and ARBs are equipotent with respect to their antihypertensive effect, [26] [27] [28] [29] [30] [31] [32] [33] there are, however, several clinically important differences between the two classes of drugs ( Figure 5 ). There is recent experimental evidence that up to 40% of tissue AII in the blood vessels, heart and kidneys is produced through the alternate pathway, mostly through the action of chymase and other enzymes. [34] [35] [36] This could account for the fact that AII levels after being suppressed initially by ACE inhibitors begin to rise later and almost return to baseline levels. 37 For these reasons, ARBs should be, perhaps, the preferred drugs for initiating antihypertensive therapy or even substituting previous treatment with ACE inhibitors. 37 ARBs block the action of AII at the receptor level regardless of the source of AII, in contrast to ACE inhibitors, which block only, the production of AII through the ACE. All ARBs mediate their antihypertensive effect through, selectively, blocking the AT 1 receptor and possibly, through stimulation of the AT 2 receptor by AII (Table 1) . With respect to ARB selection, this should be based on certain properties, which include duration of action, tissue penetration, expressed as volume of distribution, and their receptor attachment, whether this is surmountable or insurmountable. The pharmacokinetic profiles of the seven ARBs approved by FDA for the treatment of hypertension in the United States are listed in Table 2 . Telmisartan appears to have the longest duration of action and the largest volume of distribution among the seven approved drugs. In addition, it is an insurmountable drug with respect to its AT 1 receptor attachment, leading to slow dissociation from the receptor and thus prolongation of its effect. 38, 39 Telmisartan is highly selective for the AT 1 receptor and has no affinity for the AT 2 receptor. By attaching itself to the AT 1 receptor and leaving the AT 2 receptor free, it exerts a dual effect. It prevents the harmful effects of AIImediated vasoconstriction, sodium reabsorption, blood pressure elevation and the cardiovascular remodelling effects and at the same time, by not attaching to the AT 2 receptor, allows for the free AII to attach to the unoccupied AT 2 receptor and thus mediate all the beneficial effects through this receptor, such as vasodilation, decreased sodium reabsorption, and its antigrowth effects (Table 1) . Recent studies have shown that stimulation of the AT 2 receptor increases the production of bradykinin, PGE 2 and NO, leading to arteriolar vasodilation and Treatment of cardiovascular diseases SG Chrysant et al suppression of cell growth and proliferation. [40] [41] [42] [43] Therefore, the inability of ARBs to prevent kinin degradation in contradistinction to ACE inhibitors is compensated by their ability to increase kinin production through the AT 2 receptor. Although these actions are shared by all ARBs, telmisartan has the additional advantage of being longer acting and more efficacious with respect to its antihypertensive effects and to effectively suppress the rise of blood pressure during the early hours of the morning when it is needed the most. Telmisartan administered in single daily doses of 40 and 80 mg was superior to placebo, losartan 50 mg/day, valsartan 80 mg/day and amlodipine 5 mg/day in lowering the systolic blood pressure (SBP) and diastolic blood pressure (DBP) and preventing their early morning rise as illustrated in Figure 6a and b for the SBP and DBP, respectively. 44, 45 In another double-blind, 46 In other short-term studies, telmisartan was as effective or better than atenolol, 47 enalapril 48 and lisinopril. 49 Telmisartan has also been combined with a low-dose diuretic for better blood pressure control. In several short-term studies, a fixed combination of telmisartan 40 or 80 mg/day in combination with hydrochlorothiazide 12.5 mg was more effective than the single drugs, with the combination of telmisartan 80 mg/hydrochlorothiazide 12.5 mg being the most effective. [50] [51] [52] [53] An ARB-diuretic combination makes a lot of physiologic sense because each drug has a different mechanism of action, each being complementary to the other. Diuretics increase salt and water excretion and cause plasma volume contraction and decrease in blood pressure, resulting in stimulation of renin release and increased production of AII and aldosterone, which cause vasoconstriction, increase in systemic vascular resistance and salt and water retention, leading to increase in blood pressure, thus counter-balancing the hypotensive effect of diuretics.
Blood pressure-independent effects of ARBs
It is well recognized that blood pressure reduction is the most critical factor in preventing or reversing cardiovascular remodelling and target organ damage. However, several small as well as large outcome studies have shown that ARBs produce a blood pressure-independent effect similar to the one demonstrated earlier for the ACE inhibitors, [54] [55] [56] [57] as has been demonstrated by several studies. In a small double-blind study, 69 untreated hypertensive patients with LVH were randomized to treatment with valsartan 80 mg/day (n ¼ 34), or atenolol 50 mg/day (n ¼ 35) and followed for 8 months. Hydrochlorothiazide could be added for better blood pressure control. Both drugs effected similar reductions in blood pressure, but valsartan resulted in greater reduction in LVH than atenolol. 58 Similar results were reported from a large, double-blind, multicentre study in high-risk hypertensive patients with LVH. 15 In this study, 9193 patients were randomized to either losartan 50 mg/day (n ¼ 4605) or atenolol 50 mg/day (n ¼ 5488), and followed for 54 months. The dose of the baseline drugs could be doubled and other drugs could be added for better blood pressure control. Although both drug regimens lowered the blood pressure by the same magnitude, the losartanbased regimen decreased LVH, cardiovascular mortality and morbidity and new onset diabetes mellitus more than atenolol. Similar results with the above studies were demonstrated by another smaller study. In this study, 115 hypertensive patients with LVH were randomized to irbesartan 150 mg/day (n ¼ 56) or atenolol 50 mg/day (n ¼ 58), and other drugs could be added for better blood pressure control. After 48 weeks of treatment, the irbesartanbased regimen resulted in greater LVH reduction than atenolol for the same decrease in blood pressure. 59 These blood pressure-independent effects of ACE inhibitors and ARBs have been attributed to the blockade of AII and its tissue trophic cascade. This concept is reinforced from the results of another double-blind study comparing candesartan vs enalapril. In this study, 239 hypertensive patients with LVH were randomized to enalapril 10-20 mg/day (n ¼ 124) or candesartan 8-16 mg/day (n ¼ 115) and followed for 48 weeks. Both enalapril and candesartan reduced blood pressure and LVH to the same degree. 60 Three other large, double-blind cardiovascular outcome studies are currently in progress. In the Ongoing Telmisartan Alone and in combination with Ramipril Trial (ONTARGET) study, 61 23 400 high-risk patients with established coronary artery disease, stroke and peripheral vascular disease are equally randomized to telmisartan 80 mg once daily, ramipril 10 mg once daily, or their combination 80 þ 10 mg once daily and will be followed for 5 years. In the Telmisartan Randomized Assessment Study in ACEI-intolerant patients with Cardiovascular Disease (TRANS-CEND), 5000 ACEI-intolerant patients from the ONTARGET population are randomized to either telmisartan 80 mg once daily or placebo and will be followed for 5 years. 61 In the Valsartan Antihyper- tensive Long-term Use Evaluation (VALUE) study, 62 15 314 high-risk hypertensive patients are randomized to either valsartan 80 mg once daily, or amlodipine 5 mg once daily and will be followed for 4 years. The premise of this study is that valsartan will be superior to amlodipine in decreasing cardiovascular morbidity and mortality for the same decrease in blood pressure. The results of these studies are awaited with great interest because they will provide useful information regarding the 
Other benefits of ARBs
Angiotensin receptor blockers have been shown to be effective, besides hypertension and LVH, in patients with diabetic nephropathy and heart failure.
Diabetic nephropathy
Angiotensin receptor blockers, like ACE inhibitors, have been shown to be effective in reducing urinary protein excretion and to slow or prevent the progression of renal function to end-stage renal disease (ESRD) in hypertensive patients with and without diabetes mellitus. [63] [64] [65] [66] [67] [68] [69] [70] [71] The protein leakage in diabetic hypertensive patients has been attributed to endothelial dysfunction, which is present in both diabetes and hypertension. 72 Microalbuminuria in type II diabetic, 73 or nondiabetic hypertensive 74 patients has been associated, besides renal failure, with cardiovascular complications. The latter study 74 showed that for every 10-fold increase in the urinary albumin-creatinine ratio, the composite end point (death, MI or stroke) was increased by 57%, cardiovascular mortality by 97.7%, all cause mortality by 75.2%, stroke by 51% and MI by 45%. ARBs like ACE inhibitors, in contrast to other drugs, exert a greater reduction on albuminuria, which is independent of their blood pressure effect. In a double-blind study, 332 type II diabetic hypertensive patients with microalbuminuria were randomized to either valsartan 80 mg once daily (n ¼ 161) or amlodipine 5 mg once daily (n ¼ 161) and followed for 24 weeks. The dose of the drugs could be doubled and bendrofluazide could be added to bring blood pressure to 135/85 mmHg. Valsartan lowered the albumin excretion rate by 44 vs 8% for amlodipine, which was independent of blood pressure reduction. 68 Similar results have been reported in two other large multicentre, doubleblind clinical outcome studies. In one, 1715 type II diabetic hypertensive patients were randomized to irbesartan 300 mg once daily, (n ¼ 579) amlodipine 10 mg once daily (n ¼ 567) or placebo (n ¼ 569) and followed for 2.6 years. 70 Irbesartan decreased the composite end point of doubling the baseline serum creatinine, ESRD, or death from any cause by 20% vs placebo (P ¼ 0.02), and 23% vs amlodipine (P ¼ 0.006) in addition to decreasing the urinary albumin excretion rate. In the other, 1513 type II diabetic, hypertensive patients were randomized to losartan 50-100 mg once daily (n ¼ 751) or placebo (n ¼ 762) and followed for 3.4 years. 71 In both studies, additional drugs could be added for better blood pressure control. The losartan-based regimen decreased, doubling the baseline serum creatinine level by 25% vs placebo (P ¼ 0.006), and ESRD by 28% vs placebo (P ¼ 0.002), but had no effect on death rate. Another smaller study, still in progress, is comparing telmisartan 40-80 mg once daily vs enalapril 10-20 mg once daily in 252 type II diabetic hypertensive patients to determine their effects on renal and cardiovascular outcomes. 75 
Heart failure
Large clinical outcome studies have shown that ARBs, like ACE inhibitors, are effective in reducing the cardiovascular morbidity and mortality in patients with heart failure. [77] [78] [79] [80] In the ELITE II study, 76 3152 elderly patients with heart failure were randomized to losartan 50 mg once daily (n ¼ 1578), or captopril 50 mg thrice daily (n ¼ 1564) and followed for 555 days. There was no difference between losartan and enalapril in all cause mortality or sudden death, although this study was designed as a superiority study for losartan. A similar study (OPTIMAAL) recently published 77 used the same treatment schedule like the ELITE II trial on 5477 post-MI patients with heart failure mean age (67.479.8 years). They were randomized to either losartan 50 mg once daily (n ¼ 2744), or captopril 50 mg thrice daily (n ¼ 2733) and followed for 2.7 years. There was no significant difference in the all cause mortality between losartan (18%) vs captopril (16%), sudden cardiac death or resuscitated cardiac arrest (9 vs 7%) and fatal or nonfatal MI (14 vs 14%). The results of this study were not so optimal for losartan, like those of the ELITE II study. However, this study has been criticized like the ELITE II study for undertreatment with losartan vs captopril. Whether this is true or not, will be perhaps answered from an ongoing study 'Heart Failure Endpoint Evaluation with Angiotensin II Antagonist Losartan (HEAAL).' This study compares losartan 50 vs 150 mg/day in patients with heart failure intolerant to ACE inhibitors. 78 The results of the studies using valsartan were different from the losartan studies. In the Val-HeFT study, 79 5010 patients with heart failure were randomized to valsartan 160 mg twice daily (n ¼ 2511) or to placebo (n ¼ 2499) in addition to their standard treatment, which included ACE inhibitors in the great majority of patients and were followed for a mean of 23 months. Although there was no difference in the overall mortality between the two groups, the valsartan-based regimen resulted in a lower combined end point of mortality and morbidity by 13.2% (P ¼ 0.009) than the placebo group. Also, in a subgroup of patients who were intolerant to ACE inhibitors, valsartan exerted a favourable cardiac remodelling effect by improving ventricular structure and function. 80 In a study similar to Val-HeFT, the 'CHARM-Added Trial', 2548 patients with heart failure and reduced left ventricular systolic function were randomized to either candesartan 32 mg/day (n ¼ 1276) or placebo (n ¼ 1272) in addition to their standard heart failure treatment and followed for 41 months. 81 The candesartan-based regimen resulted in a lower primary end point of total mortality, as well as any secondary end points other than the placebo-based regimen (P ¼ 0.01). In a substudy, 2025 patients intolerant to ACEIs were randomized to either candesartan 32 mg/day (n ¼ 1013) or placebo (n ¼ 1015) and followed for 33.7 months; 82 candesartan reduced the composite end point of cardiovascular death or hospital admissions for CHF by 30% compared to placebo (Po0.0001). The results of the recently published VALIANT study 83 were somewhat different from the Val-HeFT and CHARM studies. This large multicentre, multinational study randomized 14 703 post-MI patients with left ventricular dysfunction, heart failure, or both 0.5 to 10 days post-MI into (1) valsartan 20 mg/ day advanced as tolerated to 160 mg twice daily (n ¼ 4909), (2) valsartan 20 mg/day plus captopril 6.25 mg/day advanced as tolerated to valsartan 80 mg twice daily plus captopril 50 mg thrice daily (n ¼ 4885), (3) captopril 6.25 mg/day advanced as tolerated to 50 mg thrice daily (n ¼ 4909), and followed them for an average of 24.7 months. The results of this study showed no difference in all cause mortality between the three treatment groups (19.9, 19.3 and 19.5%) for valsartan alone, valsartan plus captopril, or captopril alone, respectively. Also, there were no differences among the three treatment groups with respect to secondary end points of cardiovascular death, recurrent MI or hospitalization for heart failure. The overall results of this study are similar to those of the ELITE II and OPTIMAAL studies, and differ somewhat from the Val-HeFT study. In the VALIANT study, patients receiving triple therapy with valsartan, captopril and beta-blockers did not demonstrate increased mortality as did those in the Val-HeFT study.
The place of telmisartan in the treatment of hypertension
Telmisartan has been only approved by FDA for the treatment of hypertension, and so far there are no large clinical outcome studies published to demonstrate its effectiveness in patients with diabetic nephropathy or heart failure. The two large clinical outcome studies ONTARGET and TRANSCEND in high-risk patients with existing cardiovascular diseases are still in progress and the evidence so far is that the treatments are working. The smaller study on hypertensive patients with diabetic nephropathy is also in progress. At present, there are six classes of antihypertensive drugs available for the doctor to choose from to treat hypertension. Of these, the ones that block the RAAS have shown to provide the greatest protection against cardiovascular and renal remodelling and to decrease cardiovascular and renal morbidity and mortality, as has been discussed previously. Also, these studies have shown that ACEIs and ARBs are similar to each other, and possibly, the ACE inhibitors have a more favourable effect in patients with heart failure than ARBs, and should be considered the first choice of treatment in such patients. The theoretical advantage of ARBs of being complete blockers of AII in contrast to ACE inhibitors, which only block the AII generated through the classical pathway, has not materialized clinically. The only clinically important advantage of ARBs over ACEIs is their better tolerance and safety with respect to cough and angioedema. Of the six available ARBs including the latest addition of olmesartan medoxomil, 84 telmisartan has the longest duration of action and the largest volume of distribution. 85 This drug given in single daily doses of 40-80 mg alone and especially in combination with low-dose hydrochlorothiazide (12.5-25 mg/ day) provides 24-h blood pressure control including the early morning hours after awakening from sleep, when the blood pressure and the cardiovascular complications are the highest. However, one should not ignore the fact that blood pressure control is the most important point besides the agent chosen. The recently published ALLHAT study 86 showed that diuretics are as effective as calcium channel blockers and ACEIs in reducing cardiovascular and renal mortality and morbidity. This large (33 357) high patient-risk study showed that multiple drug therapy is often necessary to bring blood pressure to goal. Based on the results of the ALLHAT study, as well as other large outcome studies, the 7th Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC7 Report) stresses the significance of uncontrolled hypertension as the major cardiovascular risk. 6 Since good blood pressure control to p140/90 and p130/80 mmHg for diabetic hypertensive patients cannot be achieved with a single drug, the committee recommends the use of drug combinations, especially if the sitting blood pressure is 4160/100 mmHg. In such cases, one should initiate treatment with a combination of two drugs and preferably one should be a diuretic, if there are no compelling reasons not to use it. The most effective ones are combination of a diuretic with an ARB and ACEI. If a two-drug combination does not work, other drugs from a different class should be added until blood pressure reaches the expected goal. With respect to treatment of black hypertensive patients, who are, usually, resistant to monotherapy with ARBs or ACEIs because they are low renin hypertensives, 87 the addition of a diuretic to an ARB or ACEI, eliminates this difference and black patients respond to these regimens similarly to whites. 88 Hypertensive patients with type II diabetes mellitus and diabetic nephropathy should preferably be treated with ARBs according to the recommendations of the American Diabetes Association. 89 However, post-MI patients complicated with heart failure or left ventricular systolic dysfunction should preferably be treated with ACEIs, except for those who are ACEI intolerant. In such cases, ARBs should be used instead, until new evidence points to the contrary.
